drugset / Trial / NCT05684731
Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer
Phase 1
Recruiting
30 enrolled
Tongji Hospital
People's Hospital of Quzhou · collabQilu Hospital of Shandong University · collabShenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if KM1 is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer, and explore the Recommend Phase 2 Dose (RP2D) of KM1 in the treatment of patients with recurrent or refractory ovarian cancer.
Timeline
- Start
- 2023-02-01
- Primary completion
- 2025-06-01
- Completion
- 2026-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KM1 | Unknown | — | Other |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |